Wednesday April 24, 2019 0 comments
FORT COLLINS -- KromaTiD, Inc. announced that after successfully meeting Phase 1 grant milestones, the company has been awarded Phase 2 funding from a Fast Track Small Business Innovation Research (SBIR) grant from the National Human Genome Research Institute.
The SBIR program enables scientific excellence and technological innovation by incentivizing small businesses to engage in commercial research and development.
The combined Phase1/2 award -- totaling $900,000 -- is funding the further development of an automated, whole-genome directional Genomic Hybridization (dGH™) platform.
KromaTiD's proprietary dGH technology is a single-cell structural genomics technology, uniquely capable of the de novo measurement of random, low frequency and complex structural variations. By directly reading the chromosomal structure of many individual cells, dGH provides unique, quantitative structural genomic data unavailable by other methods.
"We are very excited by our progress toward automating our platform and the prospect of providing our customers with a whole genome, high resolution structural genomic solution," said Christopher Tompkins, KromaTiD's president and CTO.
"The funding from the NHGRI has been critical in positioning our company to meet the growing structural genomic demands of our Pharma, BioPharma and therapeutic gene-editing company customers."